Loading
A phase 3 trial of Nivolumab in melanoma, run by Biocad, active and no longer recruiting.
Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin is a phase 3 interventional study registered as NCT06640530 by Biocad, with 392 participants planned, started 2024-03-21 and due to reach its primary completion in 2025-12. Interventions recorded: BCD-263, Opdivo. Conditions listed: Advanced Melanoma, Melanoma (Skin). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/